IndicationNovartis2017-11-23 08:53Read 0
The CML medication can now treat paediatric patients
Combinationnice.org.uk2017-11-16 08:31Read 5
Palbociclib and ribociclib have received approval by NICE for the treatment for women with previously untreatable advanced breast cancer.
medical appliancesFDA2017-11-15 09:53Read 3
Offering both the promise of better patient compliance with health care, but also fears of a medical "Big Brother," a newly approved "digital pill" allows physicians to track whether or not it's been ingested by patients.
sNDAMerck2017-11-10 08:34Read 12
CMV Prophylaxis with PREVYMIS Associated with Lower All-Cause Mortality Through Week 24 and Week 48 Post-Transplant
IndicationFDA & BusinessWire2017-11-08 08:15Read 7
The U.S. Food and Drug Administration has granted regular approval to alectinib (ALECENSA, Hoffmann-La Roche, Inc./Genentech, Inc.) for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.
sNDAFDA2017-11-07 08:38Read 11
The U.S. Food and Drug Administration today expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.